BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 3127113)

  • 1. Cyclic administration of an LHRH analogue and of progesterone in risk patients to oral contraceptives.
    Geisthoevel F; Jenne D; Wieacker P; Breckwoldt M
    Contraception; 1987 Oct; 36(4):459-69. PubMed ID: 3127113
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fourteen-day versus twenty-one-day regimens of intermittent intranasal luteinizing hormone-releasing hormone agonist combined with an oral progestogen as antiovulatory contraceptive approach.
    Lemay A; Faure N
    J Clin Endocrinol Metab; 1986 Dec; 63(6):1379-85. PubMed ID: 2946711
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of ovulation during discontinuous intranasal luteinizing hormone-releasing hormone agonist dosing in combination with gestagen-induced bleeding.
    Lemay A; Faure N; Labrie F; Fazekas AT
    Fertil Steril; 1985 Jun; 43(6):868-77. PubMed ID: 3158551
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Contraception by cyclic treatment with buserelin and progesterone].
    Wieacker P; Breckwoldt M; Greif M; Geisthövel F
    Geburtshilfe Frauenheilkd; 1991 Feb; 51(2):135-9. PubMed ID: 1904039
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Contraception with an LHRH agonist: effect on gonadotrophin and steroid secretion patterns.
    Kuhl H; Jung C; Taubert HD
    Clin Endocrinol (Oxf); 1984 Aug; 21(2):179-88. PubMed ID: 6432376
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ovarian sonographic findings during intermittent intranasal luteinizing hormone-releasing hormone agonist sequentially combined with an oral progestogen as antiovulatory contraceptive approach.
    Lemay A; Faure N; Bastide A
    Fertil Steril; 1987 Jan; 47(1):60-6. PubMed ID: 2947818
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serum levels of FSH, LH, estradiol-17 beta and progesterone following the administration of a combined oral contraceptive containing 20 micrograms ethinylestradiol.
    Carlström K; Lunell NO; Zador G
    Gynecol Obstet Invest; 1978; 9(6):304-11. PubMed ID: 754992
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Luteolytic activity of LHRH and [D-Ser(TBU)6, des-Gly-NH2(10)]LHRH ethylamide: a new and physiological approach to contraception in women.
    Lemay A; Labrie F; Raynaud JP
    Int J Fertil; 1980; 25(3):203-12. PubMed ID: 6108931
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Serum levels of d-norgestrel, luteinizing hormone, follicle-stimulating hormone, estradiol, and progesterone in women during and following ingestion of combination oral contraceptives containing dl-norgestrel.
    Brenner PF; Mishell DR; Stanczyk FZ; Goebelsmann U
    Am J Obstet Gynecol; 1977 Sep; 129(2):133-40. PubMed ID: 900174
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative studies of the ethynyl estrogens used in oral contraceptives. III. Effect on plasma gonadotropins.
    Goldzieher JW; de la Peña A; Chenault CB; Cervantes A
    Am J Obstet Gynecol; 1975 Jul; 122(5):625-36. PubMed ID: 1146928
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pulsatile luteinizing hormone patterns in long term oral contraceptive users.
    Hemrika DJ; Slaats EH; Kennedy JC; de Vries Robles-Korsen TJ; Schoemaker J
    J Clin Endocrinol Metab; 1993 Aug; 77(2):420-6. PubMed ID: 8345046
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effect of deliberate omission of Trinordiol or Microgynon on the hypothalamo-pituitary-ovarian axis.
    Smith SK; Kirkman RJ; Arce BB; McNeilly AS; Loudon NB; Baird DT
    Contraception; 1986 Nov; 34(5):513-22. PubMed ID: 3102162
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Influence of oral contraceptives on integrated secretion of gonadotropins.
    Dericks-Tan JS; Gudacker V; Taubert HD
    Contraception; 1992 Oct; 46(4):369-77. PubMed ID: 1486775
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interference with ovulation by sequential treatment with the antiprogesterone RU486 and synthetic progestin.
    Kekkonen R; Alfthan H; Haukkamaa M; Heikinheimo O; Luukkainen T; Lähteenmäki P
    Fertil Steril; 1990 Apr; 53(4):747-50. PubMed ID: 2108063
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pituitary and ovarian function in women receiving hormonal contraception.
    Cohen BL; Katz M
    Contraception; 1979 Nov; 20(5):475-87. PubMed ID: 393456
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ovulation inhibition with nafarelin acetate nasal administration for six months.
    Brenner PF; Shoupe D; Mishell DR
    Contraception; 1985 Dec; 32(6):531-51. PubMed ID: 2936564
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Laboratory criteria for menopause in women using oral contraceptives.
    Creinin MD
    Fertil Steril; 1996 Jul; 66(1):101-4. PubMed ID: 8752618
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Endometrial histology during intermittent intranasal luteinizing hormone-releasing hormone (LH-RH) agonist sequentially combined with an oral progestogen as an antiovulatory contraceptive approach.
    Lemay A; Jean C; Faure N
    Fertil Steril; 1987 Nov; 48(5):775-82. PubMed ID: 2959569
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Effect of the steroid sex hormones on the LH and FSH responses to LHRH in the normal subject].
    Lemarchand-Béraud T; Reymond M; Rappoport G; Magrini G; Gomez J
    Pathol Biol (Paris); 1975 Dec; 23(10):917-22. PubMed ID: 772543
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intravaginal contraception with the synthetic progestin, R2010.
    Toivonen J
    Contraception; 1979 Nov; 20(5):511-8. PubMed ID: 527342
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.